SCHEMBL16631570

SCHEMBL16631570

O=c1ncc([C@@H]2O[C@H](CO)C(O)[C@@H]2O)c(F)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PYGL P06737 5/20 0.44
PNP P00491 3/20 0.43
SLC5A2 P31639 2/20 0.41
MAPT P10636 2/20 0.39
CDA P32320 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
STAT6 P42226 1/20 0.39
HIF1A Q16665 1/20 0.39
PAX8 Q06710 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631503 0.90 PYGL (0.38) PYGLPNPSLC5A2MAPTCDA
SCHEMBL16631377 0.85 PNP (0.36) PYGLPNPSLC5A2MAPTCDA
SCHEMBL29634939 0.84 PYGL (0.44) PYGLPNPMAPTGMNNLMNA
SCHEMBL16631516 0.84 PYGL (0.44) PYGLPNPSLC5A2MAPTCDA
SCHEMBL16631825 0.82 PYGL (0.43) PYGLPNPMAPTCDAKDM4E
SCHEMBL16631575 0.81 TSHR (0.37) MAPTLMNAPMP22SMN1; SMN2TSHR
SCHEMBL16631838 0.79 PYGL (0.40) PYGLPNPSLC5A2MAPTCDA
SCHEMBL16781790 0.78 SLC28A1 (0.46) PYGLPNPSLC5A2
SCHEMBL16805391 0.78 SLC28A1 (0.46) PYGLPNPSLC5A2
SCHEMBL18871319 0.78 SLC28A1 (0.46) PYGLPNPSLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 PYGL 649/4885PNP 7/4885SLC5A2 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.